Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.
Windtree Therapeutics, Inc. (WINT) generates news across biotechnology, licensing, financing and corporate diversification activities. Company press releases highlight its evolution from a biotechnology focus into a diversified business with several divisions and an emphasis on becoming a revenue generating company. For followers of WINT news, this means updates can span drug development milestones, asset sales, licensing income opportunities, environmental services initiatives, fintech transactions and capital markets activity.
In the biotech arena, Windtree’s news flow has included interim data and scientific presentations for its cardiovascular drug candidate istaroxime and related SERCA2a activators, as well as decisions to adjust or terminate specific clinical studies based on resources and strategic priorities. The company has also reported on strengthening its patent estate for these cardiovascular assets and later announced an agreement to sell its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC while retaining rights to a share of future proceeds and transferring certain development payables.
Windtree’s communications also cover its acute pulmonary franchise, where a global license agreement for RDS treatments such as SURFAXIN, lyophilized lucinactant and AEROSURF may generate milestone and royalty payments if development and commercialization progress under the licensee. Additional news items describe corporate strategy decisions, including a focus on environmental services and other revenue generating businesses, a letter of intent to acquire CommLoan, Inc. in the fintech and commercial real estate lending technology space, and the outcome of stockholder votes supporting financing flexibility.
Investors tracking WINT-related headlines will also see coverage of financing arrangements, preferred stock conversions, equity line of credit structures, and the company’s exploration of a BNB cryptocurrency treasury strategy, as well as its transition from the Nasdaq Capital Market to over-the-counter trading. Bookmarking this news feed can help readers monitor how Windtree’s mix of biotech assets, licensing agreements and diversified business initiatives evolves over time.
Windtree Therapeutics announced a late-breaker presentation at the European Society of Cardiology Heart Failure Conference on May 22, 2022, detailing the efficacy of Istaroxime for pre-cardiogenic shock. The Phase 2 SEISMiC study showed that patients receiving Istaroxime significantly improved systolic blood pressure compared to controls. Cardiogenic shock, with a significant global market value of $1.25 billion, underscores the need for effective treatments. A conference call will follow the presentation to discuss additional study data.
Windtree Therapeutics announced positive results from the SEISMiC Phase 2 study of istaroxime in treating early cardiogenic shock. The trial, involving 60 patients, demonstrated significant improvements in systolic blood pressure (SBP) compared to placebo. This study is pivotal as it addresses a critical need in cardiogenic shock management, which currently lacks effective pharmacological options. The results will be further detailed at the European Society of Cardiology Heart Failure meeting scheduled for May 21-24, 2022, highlighting the potential for istaroxime as a first-in-class treatment.
Windtree Therapeutics to Present at Lytham Partners Conference
Windtree Therapeutics, Inc. (NASDAQ: WINT) announced that its CEO Craig Fraser will present at the Lytham Partners Spring 2022 Investor Conference on April 4, 2022, at 11:00 AM. The conference will be held virtually from April 4-7, 2022. Interested parties can click HERE for the live webcast. The company focuses on developing late-stage interventions for acute cardiovascular and pulmonary disorders, including its lead candidate, istaroxime, for acute heart failure.
Windtree Therapeutics (WINT) reported its fourth-quarter and full-year 2021 financial results, highlighting significant progress in clinical trials, particularly the completion of enrollment in the istaroxime phase 2 study for early cardiogenic shock. The company faced a net loss of $13.1 million in Q4 2021, up from $7.5 million in Q4 2020, and a full-year net loss of $67.6 million, compared to $32.6 million a year prior. Cash resources were $22.3 million as of December 31, 2021, expected to last into Q1 2023, supporting ongoing clinical development and patent protections into 2039.
Windtree Therapeutics announced positive results from its Phase 2 study of lucinactant (KL4 surfactant) for treating critically ill patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS). The trial demonstrated that lucinactant was generally safe and well tolerated for intratracheal administration. Key findings included easier administration compared to previous formulations, stable or improved oxygenation in patients, and support for further development of this treatment approach, indicating potential for addressing ARDS from COVID-19 and other causes.
Windtree Therapeutics (NasdaqCM: WINT) has completed enrollment for its phase 2 study of istaroxime targeting early cardiogenic shock due to heart failure. The randomized, double-blind, placebo-controlled trial enrolled 60 patients, with 30 receiving istaroxime. Primary outcomes focus on systolic blood pressure (SBP) over 6 hours, with topline data expected in April 2022. Cardiogenic shock represents a critical need for new treatments, as current options have severe side effects. With a potential market value of $1.25 billion, istaroxime may address a significant gap in therapy.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present a corporate overview at the Oppenheimer 32nd Annual Healthcare Conference on March 15 at 1:20 p.m. ET. The presentation aims to highlight Windtree's advancements in treatments for acute cardiovascular and pulmonary disorders, primarily focusing on their lead candidate, istaroxime, for acute heart failure. Investors can view the live webcast and subsequent replay on the company's investor page.
Windtree Therapeutics (WINT) has completed enrollment in its Phase 2 study of lucinactant for COVID-19 associated lung injury and acute respiratory distress syndrome (ARDS). The trial involves 20 patients and aims to assess the safety and tolerability of lucinactant delivered via an endotracheal tube. Results are expected in Q1 2022. Lucinactant, designed to mimic human surfactant, may alleviate surfactant deficiency caused by COVID-19, potentially improving lung function. The company is also developing treatments for acute cardiovascular conditions.
Windtree Therapeutics announced the issuance of U.S. Patent No. 11197869, covering the intravenous delivery of istaroxime for treating acute heart failure, protecting its intellectual property until late 2039. This patent allows for longer infusion durations, enhancing outcomes related to diastolic function. Istaroxime, a dual mechanism therapy, has shown significant improvements in cardiac function and has received FDA Fast Track designation. Windtree plans to expand its intellectual property around istaroxime as it approaches crucial clinical study results in 2022.
Windtree Therapeutics is advancing its study on istaroxime for early cardiogenic shock patients, highlighting the urgent need for new treatments; inpatient mortality rates reached 30% in 2020 for this condition. The company aims to complete its phase 2 study, evaluating istaroxime's effectiveness to improve blood pressure and cardiac function without severe side effects. Results are expected in Q1 2022, aiming for regulatory discussions to expedite development.
FAQ
What is the current stock price of Windtree Therapeutics (WINT)?
What is the market cap of Windtree Therapeutics (WINT)?
